Contribute Try STAT+ Today

WASHINGTON — A top Food and Drug Administration official seemed to suggest that the new “right-to-try” law, which skirts around the FDA’s traditional authority to help patients get access to unapproved therapies, might have harmful consequences.

Dr. Peter Marks, director of the Center for Biologics Evaluation and Research, said the agency’s experience with stem cell clinics might foreshadow its future with right to try. He pointed to some clinics that purported to treat patients for a variety of conditions and instead ended up blinding them or causing tumors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.